总体生存率作为癌症药物试验中的安全护
1Health Economics and Health Technology Assessment Unit, NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; School of Business and Centre for Health Research, University of Southern Queensland, Toowoomba, Queensland, Australia.
Journal of cancer policy
|November 11, 2025
概括
这项研究提出了一个框架,将整体存活率 (OS) 作为最终的终点和瘤学试验中的安全防护. 这种方法旨在确保患者的净益,并防止代用终点错过的伤害.
科学领域:
- 在瘤学瘤学.
- 临床试验设计 临床试验设计
- 监管科学 监管科学
背景情况:
- 替代终点加速瘤药物获取,但对患者净益处产生不确定性.
- 当前的试验设计可能无法充分检测伤害,如果仅依赖中间措施.
研究的目的:
- 提出一个务实的框架,将整体存活率 (OS) 重新确立为最终的以患者为中心的疗效终点和关键的安全护.
- 解决替代终点在检测净伤害方面的局限性,并确保在瘤学药物评估中为患者带来好处.
主要方法:
- 通过预先指定操作系统的损害边际和支持事件驱动的后续行动来设计排除危害.
- 用治疗政策估计和因果敏感性分析处理交叉和后进展疗法.
- 具有验证档案的替代品的有纪律的使用和对危害边界的持续OS评估.
- 通过持续的结果收集和结构化的临界点分析,防止缺失驱动的偏见.
主要成果:
- 拟议的框架通过优先考虑整体存活率 (OS) 来提高临床试验结果的可靠性.
- 它提供了一种结构化的方法来管理代用终点,交叉和数据缺失,确保对患者净益处的可靠评估.
- 实施OS作为安全护加强了试验的可信性和患者保护.
结论:
- 将整体存活率 (OS) 作为安全护的运行,对于保护患者和提高癌症试验的可信度至关重要.
- 该框架建议采用与OS成熟度一致的监管"交通灯"系统,指导药物批准和经济评估.
- 优先考虑OS确保加速获得瘤药物转化为可证明的患者净益处和安全.
相关概念视频
01:21Cancer Survival Analysis
634
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
634
01:20Comparing the Survival Analysis of Two or More Groups
542
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
542
01:15Assumptions of Survival Analysis
388
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
388
01:24Kaplan-Meier Approach
547
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
547
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K